167 related articles for article (PubMed ID: 12215561)
41. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.
Jensen MM; Kjaer A
Am J Nucl Med Mol Imaging; 2015; 5(5):431-56. PubMed ID: 26550536
[TBL] [Abstract][Full Text] [Related]
42. Proliferation PET image to characterize pathological spatial features in patients with non-small cell lung cancer: a pilot study.
Chen XT; Zhao X; Gao ZH; Gao YS; Zhang BJ; Fu Z; Mu DB; Yu JM; Meng X
Int J Clin Exp Med; 2015; 8(6):9758-64. PubMed ID: 26309653
[TBL] [Abstract][Full Text] [Related]
43. Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.
Fink JR; Muzi M; Peck M; Krohn KA
J Nucl Med; 2015 Oct; 56(10):1554-61. PubMed ID: 26294301
[TBL] [Abstract][Full Text] [Related]
44. Investigation of brain tumors using (18)F-fluorobutyl ethacrynic amide and its metabolite with positron emission tomography.
Huang YC; Huang HL; Yeh CN; Lin KJ; Yu CS
Onco Targets Ther; 2015; 8():1877-85. PubMed ID: 26244025
[TBL] [Abstract][Full Text] [Related]
45. The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.
Cammaroto G; Quartuccio N; Sindoni A; Di Mauro F; Caobelli F;
Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):1961-73. PubMed ID: 25971995
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy.
Vojtíšek R; Ferda J; Fínek J
Rep Pract Oncol Radiother; 2015; 20(3):210-6. PubMed ID: 25949225
[TBL] [Abstract][Full Text] [Related]
47. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
[TBL] [Abstract][Full Text] [Related]
48. Comparison of 4'-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) PET/CT in human brain glioma imaging.
Toyota Y; Miyake K; Kawai N; Hatakeyama T; Yamamoto Y; Toyohara J; Nishiyama Y; Tamiya T
EJNMMI Res; 2015; 5():7. PubMed ID: 25853013
[TBL] [Abstract][Full Text] [Related]
49. PET-specific parameters and radiotracers in theoretical tumour modelling.
Jennings M; Marcu LG; Bezak E
Comput Math Methods Med; 2015; 2015():415923. PubMed ID: 25788973
[TBL] [Abstract][Full Text] [Related]
50. ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Crippa F; Agresti R; Sandri M; Mariani G; Padovano B; Alessi A; Bianchi G; Bombardieri E; Maugeri I; Rampa M; Carcangiu ML; Trecate G; Pascali C; Bogni A; Martelli G; de Braud F
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):818-30. PubMed ID: 25673053
[TBL] [Abstract][Full Text] [Related]
51. In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells.
Plotnik DA; Wu S; Linn GR; Yip FCT; Comandante NL; Krohn KA; Toyohara J; Schwartz JL
Nucl Med Biol; 2015 May; 42(5):470-474. PubMed ID: 25659855
[TBL] [Abstract][Full Text] [Related]
52. PET imaging biomarkers in head and neck cancer.
Differding S; Hanin FX; Grégoire V
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):613-22. PubMed ID: 25573630
[TBL] [Abstract][Full Text] [Related]
53. Developing biomarker-specific end points in lung cancer clinical trials.
Neal JW; Gainor JF; Shaw AT
Nat Rev Clin Oncol; 2015 Mar; 12(3):135-46. PubMed ID: 25533947
[TBL] [Abstract][Full Text] [Related]
54. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Ma DJ; Galanis E; Anderson SK; Schiff D; Kaufmann TJ; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Flynn PJ; Ligon KL; Buckner JC; Sarkaria JN
Neuro Oncol; 2015 Sep; 17(9):1261-9. PubMed ID: 25526733
[TBL] [Abstract][Full Text] [Related]
55. Assessment of tumor response to chemotherapy in patients with breast cancer using (18)F-FLT: a meta-analysis.
Deng SM; Zhang W; Zhang B; Wu YW
Chin J Cancer Res; 2014 Oct; 26(5):517-24. PubMed ID: 25400416
[TBL] [Abstract][Full Text] [Related]
56. 18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts.
Trencsényi G; Márián T; Lajtos I; Krasznai Z; Balkay L; Emri M; Mikecz P; Goda K; Szalóki G; Juhász I; Németh E; Miklovicz T; Szabó G; Krasznai ZT
Biomed Res Int; 2014; 2014():787365. PubMed ID: 25309926
[TBL] [Abstract][Full Text] [Related]
57. Spatial mapping of functional pelvic bone marrow using FLT PET.
McGuire SM; Menda Y; Ponto LLB; Gross B; TenNapel M; Smith BJ; Bayouth JE
J Appl Clin Med Phys; 2014 Jul; 15(4):129–136. PubMed ID: 25207403
[TBL] [Abstract][Full Text] [Related]
58. A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.
Mena E; Lindenberg ML; Turkbey BI; Shih J; Logan J; Adler S; Wong K; Wilson W; Choyke PL; Kurdziel KA
Clin Nucl Med; 2014 Oct; 39(10):874-81. PubMed ID: 25144214
[TBL] [Abstract][Full Text] [Related]
59. Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.
Nakajo M; Nakajo M; Kajiya Y; Goto Y; Jinguji M; Tanaka S; Fukukura Y; Tani A; Higashi M
Eur Radiol; 2014 Dec; 24(12):3199-209. PubMed ID: 25120206
[TBL] [Abstract][Full Text] [Related]
60. Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention.
Sala R; Nguyen QD; Patel CB; Mann D; Steinke JH; Vilar R; Aboagye EO
PLoS One; 2014; 9(7):e101366. PubMed ID: 25003822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
